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Summary 
 
The muscular dystrophies (MDs) encompass a range of 
genetic diseases characterized primarily by skeletal 
muscle wasting, with possible weakening of the heart. 
Clinical manifestations of these diseases have been 
documented for more than a century; however, the 
molecular defects that cause MD were only discovered 
in the last twenty years. Some forms of the disease, 
including Duchenne muscular dystrophy (DMD) and 
congenital muscular dystrophy (CMD), result from 
mutations in genes coding for proteins crucial to muscle 
cell structure. In these forms of MD, symptoms result 
from a deficiency of dystrophin or an associated protein 
in the dystrophin-glycoprotein complex (DGC), a 
structure that preserves function of normal muscle 
fibers. Another form of MD, limb-girdle muscular 
dystrophy (LGMD), is caused by a mutation encoding a 
protein component of the plasma membrane. Still other 
forms of the disease exist; fascioscapulohumeral 
muscular dystrophy (FSHD) and myotonic dystrophy 
(DM) result from nucleotide repeats and silencer 
deletions on skeletal muscle genes, respectively. In 
these forms of MD, symptoms are due to abnormal pre-
mRNA splicing. This paper reviews current literature on 
the molecular basis and therapeutic strategies of five 
types of MD.  
 
Introduction 
 
The muscular dystrophies (MDs) represent a range of 
inherited disorders in which progressive muscle wasting is 
manifest primarily in skeletal muscle, with possible 
weakening of the heart (Worton et al., 2001). Symptom 
severity varies between disease forms and may even 
fluctuate within one type of disorder (Worton et al., 2001).  
The MDs were initially classified by clinical criteria; 
however, the 1980’s discovery of dystrophin deficiency as 
the cause of Duchenne muscular dystrophy (DMD) 
represented the beginning of MD classification at the 
molecular level (Worton et al., 2001). In the last twenty 
years, genetic research has explored the molecular defects 
responsible for the disease. Some forms of MD are caused 
by protein deficiencies in the dystrophin-glycoprotein 
complex or muscle cell membrane; other forms are the result 
of abnormal splicing of pre-mRNAs necessary for muscle 
cell regulation (Figure 1; Worton et al., 2001; Gabellini, et al). 
Although the molecular defects of the former MDs are well 
known, the defects of the latter have undergone significant 
research in the last five years and continue to be studied 
today (Worton et al., 2001).  
Despite progress in determining the molecular 
defects that cause these diseases, treatments and therapies 
for all forms of MD require additional research. Studies in the 
last five years have explored the possibilities of drug therapy 
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and gene therapy for MD treatment (Worton et al., 2001). 
Treating MD is a complex process: several types of the 
disease exist, and the scientific understanding of each form 
has progressed differently throughout history.  
DMD was first characterized by Guillaume 
Duchenne in the 1860’s.  DMD is an X-linked recessive 
disorder caused by a mutation in the dystrophin-coding DMD 
gene (Hoffman et al., 1987). The disease affects 
approximately one in 3500 males; however, boys born with 
DMD appear phenotypically normal until the age of three to 
five years (Hoffman et al., 1987).  DMD symptoms include 
skeletal muscle atrophy and cardiomyopathy, and these 
typically progress until death, which usually occurs around 
age 17 (Worton et al., 2001). Scientists uncovered the 
molecular basis of DMD in the late 1980’s. Modern DMD 
research focuses on the development of new strategies to 
treat this disease. 
Congenital muscular dystrophy (CMD) is an 
autosomal recessive disease that exists in many forms. The 
classic form is due to merosin deficiency caused by a 
mutation in the laminin 2 gene (LAMA2), an extracellular 
protein of the dystrophin-glyoprotien complex (DGC); 
(Helbling- LeClerc et al., 1995). Fukuyama MD (FCMD) and 
muscle-eye-brain disease (MEB) are congenital muscular 
dystrophies also associated with variable central nervous 
system involvement (Michele et al., 2002). These secondary 
forms are unique due to the observed brain defects, but the 
mechanism of abnormality is poorly understood and is the 
focus of current research. CMD often results in early 
childhood death, thus the search for an effective treatment is 
also a current research obstacle. 
Limb-girdle muscular dystrophy (LGMD) exists in 
more than ten forms.  Limb-girdle may be inherited as either 
an autosomal dominant or an autosomal recessive disease 
(Worton et al., 2001).  Four of the eight autosomal recessive 
forms of LGMD have mutations in genes that encode for 
different forms of sarcoglycan.  These mutations often lead 
to a loss of sarcoglycan in smooth muscle. Thirty-nine 
distinct mutations were identified by 1997: most were found 
in the gene’s large extracellular domain, and they were 
determined to cause LGMD (Worton et al., 2001).  Shoulder 
and pelvic-girdle muscle degeneration occur in all LGMD 
forms. Many LGMD symptoms are milder forms of DMD and 
BMD symptoms. Sarcoglycan mutations can also lead to 
cardiomyopathy.  Although LGMD itself does not cause 
death, muscle weakening can lead to the development of 
fatal secondary disorders.  
Facioscapulohumeral muscular dystrophy is an 
autosomal dominant disease caused by the deletion of D4Z4 
repeats containing a gene silencer. This deletion leads to 
over-expression of genes upstream (Gabellini et al., 2006). 
Facioscapulohumeral refers to the muscle degeneration that 
primarily affects the face, upper arms, and shoulder blades. 
Life expectancy is normal, but some patients become 
disabled and are restricted to a wheelchair. 
 Myotonic dystrophy (DM), first characterized in 
1909, is the most common inherited skeletal muscle disease 
in adults (Brook et al., 1992). An autosomal dominant 
disease, DM is caused by an increased number of CTG 
repeats on the DMPK gene on chromosome 19 (Brook et al., 
1992). The most common form is characterized by myotonia 
(muscle hyperexcitability), muscle wasting, and varied 
effects on the nervous system (Jiang et al., 2004). DM 
typically onsets during adolescence or early adult life; 
however, a large age range is adversely affected, and 
neonatal mortality is possible (Brook et al., 1992). 
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Figure 1. Five Common Muscular Dystrophies. While all muscular dystrophies are characterized by extensive muscle pathology, the numerous 
forms of the disease show a wide variety in their molecular basis. Of the five MD’s discussed in this paper, several share common inheritance patterns, 
but all are caused by a distinct molecular disorder within muscle cells. Due to the varied causes, muscular dystrophy is largely untreatable.  
  
 
 
Figure 2. Dystrophin Glycoprotein Complex. Mutations in genes that code for proteins in the dystrophin glycoprotein (DGC) complex result in 
various forms of MD. This complex mediates stabilization and communication among the extracellular matrix, membrane, and cytosol; thus, when DGC 
integrity is reduced diverse myopathies can occur.  
 
Duchenne muscular dystrophy 
 
The DMD gene and its protein product, dystrophin 
DMD is caused by one of several possible mutations on the 
2300-kb DMD gene, which contains 79 exons and is located 
on the X chromosome (Worton et al., 2001). Mutations result 
in deletions in the gene’s Xp21 region (Worton et al., 2001). 
These defects alter pre-mRNA reading frames by inserting 
premature stop codons that terminate translation prior to the 
synthesis of the gene’s protein product, dystrophin (Mann et 
al., 2000). Point mutations, including stop codons and 
insertions, have also been found to be responsible for the 
DMD condition (Worton et al., 2001).  
Dystrophin is one of several members of the 
spectrin family of cytoskeletal membrane proteins 
(Campbell, 1995). Preliminary research indicating a 
correlation between dystrophin absence and the DMD 
condition prompted scientists to investigate dystrophin’s role 
as a membrane protein (Campbell, 1995). They determined 
that the dystrophin of normal muscle cells localizes on the 
cytoplasmic face of the muscle cell membrane, connecting 
the sarcolemma to cytoskeletal sarcomeres (Ervasti, 2000). 
The sarcolemma-cytoskeleton connection was thus 
determined as vital to normal muscle cell function; moreover, 
dystrophin was recognized as integral to maintaining this link 
(Ervasti, 2000). 
 
Dystrophin function: its role in the DGC  
Scientists were interested in the mechanism by which 
dystrophin preserved the sarcolemma-cytoskeletal 
connection (Campbell, 1995). Research indicated that the 
presence of dystrophin correlated with that of several 
sarcolemmal glycoproteins (Campbell and Kahl, 1989). 
Additional experiments purified the dystrophin-glycoprotein 
complex (DGC), and functional analysis confirmed that the 
dystrophin component of this complex was necessary to 
maintain the sarcolemma-cytoskeleton attachment (Tinsley 
et al., 1994).  
 
Protein components of the DGC  
Three types of DGC proteins were evaluated according to 
their location on the cytoskeleton, the sarcolemma, or in the 
extracellular matrix (Tinsley et al., 1994). From this analysis, 
scientists developed a DGC complex model (Tinsley et al., 
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1994). The cytoskeletal dystrophin protein links 
transmembrane sarcolemmal glycoproteins to an actin 
component of the cytoskeleton (Figure 2; Tinsley et al., 
1994). The sarcolemmal proteins include three 
subcategories, and they function as follows: first, intracellular 
syntrophin proteins bind dystrophin; second, the 
transmembrane -dystroglycan protein attaches dystrophin 
to the extracellular -dystroglycan protein; finally, -
dystroglycan links transmembrane -dystroglycan and 
sarcoglycan proteins to the laminin a2 (also known as 
merosin) protein in the extracellular matrix (Figure 2; Tinsley 
et al., 1994). Laminin a2 connects -dystroglycan to the 
extracellular matrix (Figure 2; Tinsley et al., 1994).  
 
Dystrophin absence disrupts the DGC  
According to the DGC model, dystrophin absence causes a 
disruption in the link between -dystroglycan and the 
cytoskeleton (Figure 2; Tinsley et al., 1994). Scientists were 
interested in determining whether this disruption correlated 
with increased sarcolemmal damage; moreover, they 
explored that sarcolemmal damage could result in cell 
necrosis and loss of muscle function (Campbell, 1995). This 
pathogenesis was confirmed by evidence of increased 
sarcolemmal damage and loss of muscle function after 
muscle cell contraction in the mdx mouse, a dystrophin-
deficient animal model for human DMD (Petrof, 1993). This 
led to the modern understanding that the dystrophin 
component of the DGC mechanically reinforces the 
sarcolemma, thus preventing muscle cell death and 
preserving muscle function (Petrof, 1993).  
 
DMD treatment and strategies for the future 
Several therapies have been proposed for DMD treatment. 
Pharmacologic approaches focus on the use of 
corticosteroids, especially prednisone, to decrease muscle 
cell degeneration and enhance muscle cell strength (Worton 
et al., 2001). Such treatment successfully improves muscle 
function; however, the negative side effects of long-term 
corticosteroid therapy have decreased the feasibility of this 
treatment (Worton et al., 2001).  
As a result, recent research has explored gene 
replacement therapy as a potential DMD treatment option. 
Both cell-mediated and vector-mediated gene transfer have 
been studied. Antisense oligoribonucleotide (AO) therapy 
and adenoviral (Ad) vector therapy are two novel treatment 
strategies that have shown promise (Mann et al., 2000; 
DelloRusso et al., 2002).  
AO therapy uses antisense oligoribonucleotides 
(AOs) to block specific pre-mRNA splice sites on mutated 
DMD genes (Mann et al., 2000). This blockage induces 
excision of the mutation-containing exon and has enabled 
previously dystrophin-deficient mdx hind limb muscle cells to 
translate short dystrophin proteins (Mann et al., 2000). The 
therapy has been successful both in vivo and in vitro (Mann 
et al., 2000). Clinical significance of AO therapy depends 
upon the success of future research in delivering the therapy 
systemically, rather than through intramuscular injection 
(Mann et al., 2000).  
Adenoviral (Ad) vector therapy is another new 
DMD treatment strategy (DelloRusso et al., 2002). This 
therapy uses Ad vectors carrying full-length cDNA dystrophin 
cassettes to transduce dystrophin-deficient muscle cells, 
thereby facilitating the production of short dystrophin 
proteins (DelloRusso et al., 2002). Research on mdx mice 
has shown that a single injection of muscle-specific Ad can 
restore dystrophin levels in 25-30% of cells one month after 
treatment (DelloRusso et al., 2002). In addition, transduced 
muscle cells can exhibit up to a 40% decrease in 
sarcolemmal damage caused by contraction (DelloRusso et 
al., 2002). Future research employing uniform, rather than 
muscle-specific, Ad injection will likely facilitate even greater 
dystrophin restoration and sarcolemmal stability (DelloRusso 
et al., 2002).  
 These DMD therapies have developed from a 
thorough scientific understanding of this disease at the 
molecular level. Analysis of the DMD gene and its dystrophin 
protein product led to an evaluation of protein’s role in the 
DGC (Campbell and Kahl, 1989; Tinsley et al., 1994; Worton 
et al., 2001). Subsequent research demonstrated 
dystrophin’s vital role in the maintenance of sarcolemmal 
integrity and the preservation of muscle function (Petrof, 
1993; Tinsley et al., 1994).  
 
Congenital muscular dystrophy 
 
Characteristics of CMD 
The classic form of CMD results from a merosin deficiency. 
The absence of merosin is due to a mutation in the laminin 
2 gene (Helbling-LeClerc et al., 1995). This protein is an 
extracellular element of the dystrophin-glycoprotein complex 
(Figure 2). Absence of this protein results in muscle 
weakness because the muscle fibers are not properly 
anchored to the extracellular matrix (Helbling-LeClerc et al., 
1995). The CMDs vary in phenotype and are characterized 
by the presence of the disease at birth, thus most patients 
rarely become ambulatory (Worton et al., 2001). Despite 
normal mental development, severe muscle wasting often 
leads to early childhood death (Qiao et al., 2005). The other 
forms of CMD, Fukuyama Muscular Dystrophy and muscle-
eye brain disease affect the central nervous system. In 
FCMD and MEB, merosin deficiency is secondary to 
mutations in other genes. However, the mechanism by which 
these mutated genes are involved in brain malformation is 
currently unknown and is the primary focus of modern CMD 
research. 
 
Alternative Forms of CMD 
Secondary deficiency usually occurs in the form of 
Fukuyama Muscular dystrophy (Worton et al., 2001). This 
form of the disease is caused by a defect in the gene 
encoding for fukutin, a glycosyltransferase (Worton et al., 
2001). This secondary deficiency can also be observed 
through muscle-eye-brain disease (MEB); (Michele et al., 
2002). In MEB, the gene POMGnT1 also encodes for a 
similar glycosyltransferase. Thus, both proteins are enzymes 
with the similar function of glycosylation. When 
hypoglycosylation of dytroglucan occurs, binding to 
dystroglycan, another main component of dystrophin-
glycoprotein complex, is completely eliminated (Figure 2, 
Michele et al., 2002). Therefore, disruption of -dystroglycan 
prevents binding to: laminin, neurexin, and agrin. These 
specific findings form a unique pathogenic mechanism of 
congenital muscular dystrophies; abnormal dystroglycan-
ligand interactions result in brain malformations (Moore et 
al., 2002). Additionally, CMD is characterized by lack of a 
successful treatment. Thus, extensive CMD research 
focuses around the goal of developing a new and effective 
therapy. 
 
Gene Therapy for CMD 
Fortunately, current research focuses on methods of therapy 
for CMD patients. Gene therapy using the minigene agrin, 
known for its part in the formation of the neuromuscular 
junction, has been extensively studied using transgenic mice 
(Moll et al., 2001). The mechanism of amelioration suggests 
that agrin acts by binding the membrane and -dystroglycan 
to possibly restore muscle function in CMD patients (Moll et 
al., 2001). The absence of laminin 2 (merosin) is followed by 
the upregulation of laminin-4, which leads to upregulation of 
laminin-8. However, laminin-8 does not bind -dystroglycan 
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strongly enough to maintain the connection. Congenital 
muscular dystrophy pathology could potentially be prevented 
and possibly reversed by introducing agrin, another 
extracellular matrix component (Qiao et al., 2005). This 
occurs because agrin more effectively links the up-regulated 
laminin-8 to the muscle surface at -dystroglycan. Thus, 
agrin amends muscle function in CMD mice by stabilizing the 
-dystroglycan to restore strength of the basement 
membrane (Moll et al., 2001). However, mild signs of 
dystrophy still exist in the tested mice, suggesting that agrin 
does not completely rescue all deterioration (Moll et al., 
2001).  
Modern research allowed the development of a 
mechanism for secondary forms of CMD such as FCMD and 
MEB. Understanding the role of -dystroglycan-ligand 
interactions in brain malformation and general muscle 
wasting has guided researchers to new mechanisms of CMD 
therapy. Gene therapy using the miniagrin gene is the main 
focus of CMD symptom treatment due the proteins 
assistance in neuromuscular junctions (Qiao et al., 2005). 
However, agrin is not the complete answer since all muscle 
weakening could not be salvaged. Gene therapy via a 
transgene is also not clinically viable (Qiao et al., 2005), thus 
new methods by somatic gene transfer are also being 
explored in mouse models and can hopefully be expanded to 
studies within human patient muscle tissues.  
 
Limb-Girdle Muscular Dystrophy 
 
Disruption of SG-SSPN 
LGMD results from mutations in the genes coding for the 
sarcoglycan proteins of the DGC.  Disruption of the 
sarcoglycan-sarcospan (SG-SSPN) complex in vascular 
smooth muscle disturbs vascular function, initiates 
cardiomyopathy, and worsens muscular dystrophy (Vazquez 
et al., 1999).   
 Vazquez et al. (1999) analyzed genetically 
engineered mice deficient in either -sarcoglycan (Sgca) or 
-sarcoglycan (Sgcd). They found that while the SG-SSPN 
complex was absent in both models, only Sgcd
-1- 
mice 
developed cardiomyopathy and loss of vascular smooth 
muscle SG-SSPN complex (Vazquez et al., 1999).  In 
contrast, Sa null (Sgca 
-1-
) mice showed no morphological 
signs of cardiomyopathy although the SG-SSPN complex 
was absent from the cardiac muscle membrane.   
      The Sgcd
-1-
 and Sgca
-1-
 mice expressed the SG-
SSPN complex differently in coronary artery smooth muscle: 
-, -, and -sarcoglycan and sarcospan were expressed in 
the coronary arteries of Sgca
-1-
 mice. These proteins, 
however, were absent in Sgcd
-1-
 mice. 
 The Microfil perfusion technique was used in vivo 
to demonstrate whether disruption of the SG-SSPN complex 
in smooth muscle of coronary arteries leads to vascular 
perfusion abnormalities.  Sgcd
-1-
 mice displayed numerous 
areas of pronounced constrictions (Vazquez et al., 1999).  In 
contrast, Sgca
-1-
 mice showed coronary microvessels 
normally distributed and smoothly tapered, similar to that of 
the WT (Vazquez et al., 1999).  
  
Gene Transfer Therapy  
Limb-girdle muscular dystrophy types 2E and 2F are caused 
by mutations in the genes encoding - and -sarcoglycan 
(Durbeej et al., 2003).  Loss of sarcogylcans in smooth 
muscle was previously shown to lead to constrictions of the 
microvasculature which can then lead to cardiomyopathy 
(Durbeej et al., 2003).  Studies showed that gene transfer of 
the deleted sarcoglycan gene can help in preserving the 
sarcolemmal integrity as well as preventing pathological 
dystrophy and hypertrophy.   
 Genes were transferred via an adenovirus vector.  
Recombinant - and -sarcoglycan adenoviruses were 
injected into skeletal muscles of corresponding null mice, 
Sgcb
-1-
, mice that lacked -sarcoglycan and Sgcd-1-, and 
mice that lacked -sarcoglycan.  The adenovirus targeted 
only skeletal muscle, as it was unable to cross the 
perimysium. Both the SG-SSPN and DGC complexes were 
restored in skeletal muscle post-treatment (Durbeej et al., 
2003).  
 Treatment did not restore these complexes in 
vascular muscle.  In - and -sarcoglycan gene transfer, 
sarcoglycans were only reconstituted at the sarcolemma but 
not in the vascular smooth muscle (Durbeej et al., 2003).  
Adenovirus treatment produced some muscle cell changes: 
there were, however, fewer centrally nucleated fibers and a 
decrease in muscle mass (Durbeej et al., 2003). The latter 
change was found favorable as Sgcb
-1-
 and Sgcd
-1-
 mice 
displayed severe pathological hypertrophy (Durbeej et al., 
2003). 
 
Disruption of Calcineurin as Treatment 
Calcineurin (Cn) is a thereonine phosphatase involved in the 
regulation of differentiation-specific gene expression in 
diverse tissues (Parsons et al., 2007). Altered Cn treatment 
has prevented muscle regeneration in mdx mice; however, it 
has a different affect on LGMD mice. The effect of altered 
Cn activation treatment was studied in Sgcd
-1-
 LGMD mice: 
deletion of a loxP-targeted calcineurin B1 gene significantly 
reduced skeletal muscle degeneration in this mouse model 
(Parsons et al., 2007).   
 
NFAT 
Calcineurin expression occurs in cells involved in various 
processes, including muscle development and cardiac 
hypertrophy (Parsons et al., 2007). Calcineurin activation 
can directly dephospohorlyate specific transcription factors; 
this is referred to as nuclear factor of activated T cells 
(NFAT) (Parsons et al., 2007).   
        The -sarcoglycan gene, which encodes SG-
SSPN complex proteins that are essential to the DGC 
complex, is vital for membrane stability (Parsons et al., 
2007).  In Scgd 
-1-
 mice disruption of Cn signaling improves 
both cardiac and skeletal muscle disease: fibrosis was 
reduced; muscle degeneration and inflammation were 
improved. Mice exhibiting increased Cn expression, 
however, displayed worsened skeletal muscle 
histopathology and heart disease (Parsons et al., 2007).   
 
LGMD Treatment 
Different treatments exist for the various LGMD forms.  For 
LGMD types 2E and 2F there is some hope in gene therapy 
via adenoviruses. Recombinant - and -sarcoglycan 
adenoviruses injections have restored SG-SSP complexes in 
LGMD mice (Durbeej et al., 2003). Calcineurin signaling 
disruption has successfully improved cardiac and skeletal 
muscle disease in LGMD mice (Parsons et al., 2007).  In the 
future, these treatments may be applied to human patients.  
 
Fascioscapulohumeral muscular dystrophy 
 
Symptoms of FSHD 
Facioscapulohumeral muscular dystrophy is an autosomal 
dominant disease not due to a gene mutation, but rather to a 
deletion of a silencer which is located within D4Z4 repeats 
on chromosome 4q35. Deletion of this silencer results in 
over-expression of FRG1. A critical determinant of the 
severity of the disease is related to the number of D4Z4 
repeats. Some common symptoms of FSHD are muscle 
weakness in the face, arms, and shoulders. Another 
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common symptom of FSHD is kyphosis, the abnormal 
curvature of the spine.  
 
FSHD and mRNA populations 
A study (Tupler et al., 1999) compared FSHD mRNA 
populations to those of normal muscle. Results showed that 
muscles affected by FSHD showed intense gene expression 
alteration observed by severe under-expression or over-
expression of specific mRNAs (Tupler et al., 1999); thus, 
suggesting a misregulation of gene expression which serves 
as the basis for FSHD, providing more evidence that FSHD 
is different from other forms of MD. 
 
Repression of transcription 
Because FSHD affects transcriptional expression of the 
4q35 genes (Gabellini et al. 2002), Petrov et al. (2006) 
proposed a model for the existence of a repressive element 
in the D4Z4 repeats. This element binds to a complex 
leading to transcriptional repression and distribution to 
adjacent sequences. This model further suggests that 
deletion of a specific number of D4Z4 repeats will decrease 
the number of bound repressor complexes. Therefore, the 
transcriptional repression of 4q35 genes would also 
decrease eventually leading to FSHD.  
Since FSHD studies remain in early stages, future 
research is dedicated to developing a therapeutic treatment 
for FSHD patients. 
 
Myotonic Dystrophy 
 
Myotonic dystrophy (DM) is caused by an increased number 
of non-coding repeats in specific nucleotide sequences. The 
disease was first characterized in 1909, and its molecular 
basis was determined in 1992 (Brooks et al.). Recent 
research focuses on the more severe disease subtype, DM1. 
In DM1, the dystrohphia myotonica-protein kinase (DMPK) 
gene of chromosome 19 contains expanded trinucleotide 
CTG repeats (Brook et al., 1992). 
 The number of repeats is both proportional to 
disease severity and inversely proportional to the onset of 
the disease (Miller et al., 2000). Normal individuals have 5 to 
37 CTG repeats; mild or classic cases have 50 to 1000 
repeats; severe cases have more than 1000 repeats. Classic 
cases are characterized by late onset, myotonia and muscle 
weakness. More severe congenital DM cases can cause 
neonatal mortality or mental retardation (Brook et al., 1992). 
  
Pre-mRNA gain-of-function 
CTG repeat expansion has been linked to DM for many 
years, and its effect on RNA has been debated for almost as 
long.  
Repeat expansions form hairpin loops in the pre-
mRNA structure (Miller et al., 2000).  The loops accumulate 
and form nuclear aggregates, or foci. Foci do not directly 
cause DM (Ho et al, 2005): instead, repeat expansions 
create a toxic gain-of-function in RNA, resulting in DM 
(Phillips et al., 1998).  Many models for DM pathogenesis 
have been proposed (Jiang et al., 2004), but one has 
surfaced as the focus of recent research. Phillips et al. 
(1998) proposed that pre-mRNA gain-of-function results from 
the inappropriate binding of gene regulatory proteins to CUG 
repeats, which causes aberrant pre-mRNA alternative 
splicing (Philips et al., 1998; Ho et al., 2004; Charlet-B., 
2002).  
 
The effect of nuclear foci on gene regulatory proteins  
When first described by Philips et al. (1998), the gene 
regulatory proteins were known only as CUG- binding 
proteins (CUG-BP). Current research has identified these 
proteins.  
Two RNA-binding protein families have also been 
identified as CUG-BP: muscleblind-like proteins (MBNL) are 
involved in muscle differentiation; CELF proteins affect 
alternative splicing. Both protein families bind the CUG 
repeats. MBNL proteins colocalize with foci in the nucleus, 
which in turn decreases their activity (Miller et al., 2000). In 
knockout mice missing the mbnl1 gene, characteristic 
symptoms, such as myotonia, were seen (Kanadia et al., 
2003). This suggests that loss of MBNL protein function is a 
source of pathogenesis. While DM cells have a reduced 
amount of active MBNL, CELF proteins are found at 
increased levels and activity rates.  
Two gene regulatory protein families determine 
which pre-mRNA splicing pattern is enacted (Ho et al., 
2004).  Depending on protein quantity, exon splicing is 
activated or repressed. In normal splicing patterns, MBNL 
proteins bind to introns and CELF proteins are rarely bound 
to CUG repeats (Ho et al., 2004). Danisthong et al. (2004) 
found that decreased MBNL protein levels determine 
aberrant splicing occurrence. Without binding sites for CELF 
proteins, however, cells will not respond to CTG repeat 
expansion (Ho et al., 2004). DM is caused by splicing 
patterns formed by either low levels of MBNL proteins or 
high levels of CELF proteins binding to CUG repeats. 
 
Misspliced pre-mRNA in DM 
Once abnormal pre-mRNA splicing was found to occur in 
DM, the specific mechanism of pathogenesis could be 
determined.  
 In DM, normal muscle development is disrupted. 
Normally, fetal protein isoforms are modified into adult 
isoforms by a change in specific pre-mRNA splicing patterns. 
MBNL proteins splice fetal isoform exons and incorporate 
adult exons. However, nuclear foci sequester MBNL proteins 
disrupt splicing patterns and include fetal exons. CELF 
proteins also control fetal exon inclusion: rising CELF levels 
correspond to increased inclusion and splicing of fetal and 
adult exons, respectively.  
 MBNL and CELF proteins regulate the splicing 
patterns of mRNAs affected in DM: misregulation of the 
Clcn1 gene, which encodes proteins for skeletal muscle 
chloride channels, accounts for myotonia in DM (Charlet-B. 
et al., 2002), and missplicing of the insulin receptor (IR) gene 
creates over-expression of insulin insensitive tissue, causing 
diabetes in some DM patients (Savkur et al., 2001). 
Recent discoveries linking MBNL proteins to 
aberrant splicing and DM onset suggest possible therapies. 
Recent research by Kanadia et al. (2006) suggests that 
over-expression of MBNL proteins may restore normal pre-
mRNA splicing to DM cells. DM mice over-expressing MBNL 
exhibited neither RNA-splicing defects nor myotonia. Gene 
therapy may be a very promising future treatment for this 
type of muscular dystrophy.  
 
Cures for MD are still being discovered 
 
Due to the large variety in forms, treatments for muscular 
dystrophy are very complex.  
Recent DMD research indicates that dystrophin 
synthesis can be restored via antisense and adenoviral 
vector therapy. CMD treatment strategies focus on gene 
therapy using agrin. Modern LGMD treatments involve 
recombinant - and  -sarcoglycan adenovirus therapy, as 
well as Calcineurin disruption signaling. Current FSHD 
research is determining the pathogenic mechanism of the 
disease and developing potential therapeutic strategies. 
Current DM research suggests that gene regulatory protein 
over-expression will correct the aberrant splicing 
characteristic of the disease. Research is ongoing, and 
treatment strategies continue to be investigated. 
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